Get the Stockscreener App
5.56
2.21%
+0.12
Delcath Systems Inc stock is currently priced at $5.56, with a 24-hour trading volume of 76,812.
It has seen a +2.21% increased in the last 24 hours and a +14.17% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $5.44 pivot point. If it approaches the $5.57 resistance level, significant changes may occur.
Previous Close:
$5.44
Open:
$5.55
24h Volume:
76,812
Market Cap:
$141.44M
Revenue:
$2.07M
Net Income/Loss:
$-47.68M
P/E Ratio:
-1.6848
EPS:
-3.3
Net Cash Flow:
$-31.31M
1W Performance:
+4.91%
1M Performance:
+14.17%
6M Performance:
+78.21%
1Y Performance:
-4.47%
1D Range:
$5.44
$5.68
52W Range:
$2.25
$7.99
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
212 489 2100
Address
1633 Broadway, 22nd Floor Suite C, New York, NY
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
Delcath Systems Inc Stock (DCTH) Latest News
How Much Upside is Left in Delcath Systems (DCTH)? Wall Street Analysts Think 244.83%
Zacks Investment Research
Can Delcath Systems (DCTH) Climb 277.73% to Reach the Level Wall Street Analysts Expect?
Zacks Investment Research
Delcath Systems (DCTH) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
Netflix To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga
Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
DexCom (DXCM) Soars 9.8%: Is Further Upside Left in the Stock?
Zacks Investment Research
Delcath Systems Inc Stock (DCTH) Financials Data
Delcath Systems Inc (DCTH) Revenue 2024
DCTH reported a revenue (TTM) of $2.06 million for the quarter ending December 31, 2023, a -24.08% decline year-over-year.
Delcath Systems Inc (DCTH) Net Income 2024
DCTH net income (TTM) was -$47.68 million for the quarter ending December 31, 2023, a -30.60% decrease year-over-year.
Delcath Systems Inc (DCTH) Cash Flow 2024
DCTH recorded a free cash flow (TTM) of -$31.31 million for the quarter ending December 31, 2023, a -24.44% decrease year-over-year.
Delcath Systems Inc (DCTH) Earnings per Share 2024
DCTH earnings per share (TTM) was -$2.82 for the quarter ending December 31, 2023, a +31.94% growth year-over-year.
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
0.77%
Cap:
|
Volume (24h):